4-Bromo-2-(methylsulfonamido)benzoic acid → N-{5-bromo-2-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]phenyl}methanesulfonamide
반응식
[Br:1][C:2]1[CH:10]=[CH:9][C:5]([C:6]([OH:8])=O)=[C:4]([NH:11][S:12]([CH3:15])(=[O:14])=[O:13])[CH:3]=1.[CH3:16][C:17]1[C:18]([N:24]2[CH2:29][CH2:28][NH:27][CH2:26][CH2:25]2)=[N:19][CH:20]=[C:21]([CH3:23])[CH:22]=1>>[Br:1][C:2]1[CH:10]=[CH:9][C:5]([C:6]([N:27]2[CH2:28][CH2:29][N:24]([C:18]3[C:17]([CH3:16])=[CH:22][C:21]([CH3:23])=[CH:20][N:19]=3)[CH2:25][CH2:26]2)=[O:8])=[C:4]([NH:11][S:12]([CH3:15])(=[O:14])=[O:13])[CH:3]=1참가 물질
3
실험 절차
Using 4-bromo-2-methanesulfonylaminobenzoic acid (964 mg) described in Preparation Example 225 and 1-(3,5-dimethylpyridin-2-yl)piperazine (629 mg) described in Preparation Example 79 and by the reaction and treatment in the same manner as in Preparation Example 111, the title compound (321 mg) was obtained.
후처리
- customdescribed in Preparation Example 79 and by the reaction and treatment in the same manner as in Preparation Example 111